We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

iCAD

Offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid an... read more Featured Products: More products

Download Mobile App




AI Solution Supporting Wins Best New Radiology Solution Award

By MedImaging International staff writers
Posted on 18 Sep 2019
Print article
Image: The ProFound AI for DBT has been selected as the winner of the “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program (Photo courtesy of iCAD).
Image: The ProFound AI for DBT has been selected as the winner of the “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program (Photo courtesy of iCAD).
An FDA-cleared artificial intelligence (AI) solution that supports breast cancer detection in 3D tomosynthesis has been selected as the winner of “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program.

ProFound AI for Digital Breast Tomosynthesis (DBT) from iCAD Inc (Nashua, NH, USA) is the first and only US FDA-cleared AI solution that supports breast cancer detection in DBT, or 3D mammography. The technology is intended for use concurrently by radiologists reading DBT exams and uses a cutting-edge algorithm developed with the latest in deep learning.

Trained to detect malignant soft-tissue densities and calcifications, ProFound AI aids radiologists in breast cancer detection and is clinically proven to improve cancer detection rates, reduce false positives and unnecessary patient recalls, and decrease reading times for radiologists. The software rapidly and accurately analyzes each DBT image and provides radiologists with key information, such as Certainty of Finding and Case Scores, which assist radiologists in making clinical decisions and prioritizing caseloads.

ProFound AI for DBT runs on the PowerLook platform with NVIDIA graphical processing units (GPU). PowerLook is a flexible and reliable DICOM platform that easily integrates with image modalities, mammography review workstations, picture archiving and communication systems (PACS) and image storage systems. Leveraging the latest in GPU technology, the algorithm can rapidly process a four-view tomosynthesis case, ensuring results are available to radiologists in the most efficient manner.

“iCAD is a previous MedTech Breakthrough Award winner, and we are delighted to see the company continue to innovate. ProFound AI is a revolutionary technology built on the latest deep-learning and artificial intelligence technology that assists radiologists and addresses the challenges of reading breast tomosynthesis cases,” said James Johnson, managing director, MedTech Breakthrough. “We extend a hearty congratulations to the entire iCAD team on their innovative spirit and ability to execute on incorporating sophisticated AI technology in a platform that delivers incredibly real-world benefits.”


3T MRI Scanner
MAGNETOM Cima.X
NMUS & MSK Ultrasound
InVisus Pro
40/80-Slice CT System
uCT 528
Silver Member
X-Ray QA Meter
T3 AD Pro

Print article

Channels

MRI

view channel
Image: An AI tool has shown tremendous promise for predicting relapse of pediatric brain cancer (Photo courtesy of 123RF)

AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans

Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.